Objective: The aim of this study was to characterize patterns of local progression following resection for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-generation sequencing (NGS). Background: Progression of neoplastic disease in the remnant pancreas following resection of IPMN may include development of a new IPMN or ductal adenocarcinoma (PDAC). However, it is not clear whether this progression represents recurrence of the same neoplasm or an independent second neoplasm. Methods: Targeted-NGS on genes commonly mutated in IPMN and PDAC was performed on tumors from (1) 13 patients who developed disease progression in the remnant pancreas following resection of IPMN; and (2) 10 patients who underwent a resection for PDAC and had a concomitant IPMN. Mutations in the tumors were compared in order to determine the relationship between neoplasms. In parallel, clinical and pathological characteristics of 260 patients who underwent resection of noninvasive IPMN were reviewed to identify risk factors associated with local progression. Results: We identified 3 mechanisms underlying local progression in the remnant pancreas: (1) residual microscopic disease at the resection margin, (2) intraparenchymal spread of neoplastic cells, leading to an anatomically separate but genetically related recurrence, and (3) multifocal disease with genetically distinct lesions. Analysis of the 260 patients with noninvasive IPMNs showed that family history of pancreatic cancer (P ¼ 0.027) and highgrade dysplasia (HGD) (P ¼ 0.003) were independent risk factors for the development of an IPMN with HGD or an invasive carcinoma in the remnant pancreas. Conclusions: Using NGS, we identify distinct mechanisms for development of metachronous or synchronous neoplasms in patients with IPMN. Patients with a primary IPMN with HGD or with positive family history are at an increased risk to develop subsequent high-risk neoplasms in the remnant pancreas.
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Keywords: completion pancreatectomy, intraductal papillary mucinous neoplasms, next-generation sequencing, pancreatic cancer, targeted sequencing (Ann Surg 2017;266:133-141) I ntraductal papillary mucinous neoplasms (IPMNs) of the pancreas can progress from low to high-grade dysplasia, and ultimately to invasive carcinoma. [1] [2] [3] In addition to the progression of individual IPMNs, synchronous and metachronous development of neoplasms in the pancreas is a significant clinical problem. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Interestingly, development of invasive cancer in the remnant pancreas can manifest as either an invasive carcinoma that appears to have arisen from the IPMN, or as a de novo pancreatic ductal adenocarcinoma (PDAC) with no identifiable associated or antecedent cystic lesion. In both IPMN and conventional PDAC, it is not clear whether these neoplasms represent disease progression of the resected primary neoplasm or independent neoplasms. 16, 17 In order to answer this question, we characterized the genetic alterations of pancreatic neoplasms in patients who underwent surgical resection for IPMN and who had subsequent completion pancreatectomy for progressive disease in the remnant pancreas. We also independently sequenced IPMNs and concomitant but morphologically separate PDACs resected within a single specimen. In order to define the genetic relationship of the lesions, we compared the genetic changes in the resected primary neoplasm with those in the separate synchronous or metachronous lesions. 
METHODS

Study Population for Genetic Analysis
This study was approved by the Institutional Review Board of The Johns Hopkins Hospital. A retrospective review of a prospectively collected pancreatic resection database and the surgical pathology database of the Johns Hopkins Hospital (JHH) was performed to identify 2 groups of patients for the genetic analysis: (1) patients who underwent a completion pancreatectomy for either an IPMN or PDAC following resection of an IPMN and (2) patients who underwent a pancreatic resection for a conventional PDAC who had a morphologically separate IPMN in their resected pancreas. Conventional PDAC has been defined as PDAC that at the pathological evaluation do not arise from an IPMN. In the second instance, separation was defined pathologically as PDAC that was physically separated from IPMN by uninvolved pancreatic parenchyma. We required that there was no histologic transition from IPMN with high-grade dysplasia to the PDAC in the specimen and that both lesions did not occur in same tissue block. IPMNs were assigned to 1 of 3 categories consisting of low-grade dysplasia (LGD) or high-grade dysplasia (HGD) based on the highest grade of dysplasia encountered in the specimen, or IPMN with invasive carcinoma. 18 The study included a total of 23 patients for genetic analysis: 13 patients who underwent a completion pancreatectomy for progression in the remnant following the resection of an IPMN (Supplementary Figure 1 , http://links.lww.com/SLA/ B35), and 10 cases with separate PDAC and IPMN in the same resection.
Next-Generation Sequencing
Next-generation sequencing (NGS) assays were performed blinded to patient's clinical information. An Ion AmpliSeq Custom Panel was designed by the Ion AmpliSeq Designer (Pipeline version 4.2; Life Technologies) to perform multiplex PCR and sequencing of 11 genes (142 amplicons in 2 primer pools) known to be targeted in pancreatic ductal neoplasms and IPMNs (KRAS, GNAS, TP53, SMAD4, CDKN2A, RNF43, TGFBR2, ARID1A, BRAF, MAP2K4, and PIK3CA). [19] [20] [21] The targeted regions are described in Supplementary Table 1 , http://links.lww.com/SLA/ B35. Genomic DNA was extracted using QIAamp DNA Micro Kit (Qiagen) from matched formalin-fixed paraffin-embedded (FFPE) tumor/normal cores or 5 mm tissue sections that were manually microdissected to enrich for neoplastic cellularity. Genomic DNA was quantified by Quantifiler Human DNA Quantification kit (Applied Biosystems) before performing the NGS. Two nanograms of genomic DNA was amplified using Ampliseq reagents for the library preparation, loaded and sequenced onto a 318v2 chips using an Ion Torrent Personal Genome Machine (PGM; Life Technologies) following the manufacturer's protocols. Postsequencing data analyses, including alignment to the hg19 human reference genome and variant calling, were performed using NextGENe software (v2.4; SoftGenetics, Chicago, IL). Alignments and putative mutations were visually verified using the Integrative Genomics Viewer (IGV, v2.3; Broad Institute) and the NextGENeViewer (v2.4; SoftGenetics, Chicago, IL).
Relatedness Assessment
On the basis of the genetic alterations, we assessed the genetic relatedness of the separately dissected neoplasms from each patient. We assigned the patterns of genetic alterations to 1 of the 3 categories: ''likely independent'' when discordant mutations in driver genes were present in the 2 lesions; ''likely related'' when the 2 lesions from the same patient shared mutations in genes other than KRAS; and ''indeterminate'' when only the same KRAS mutation was present in both lesions. In fact, the main limit of this approach is the difficulty in interpreting the significance of KRAS gene mutations when they are present in both lesions. Because KRAS codon 12 hotspot mutations were very common in all of the neoplasms assayed, 2 independent lesions could indeed by chance harbor the same mutation.
Clinical Validation Study Population
Using the JHU database, we identified 634 consecutive patients who underwent a pancreatectomy for an IPMN between January 1996 and January 2014 at JHU. Patients with an unspecified IPMN grade of dysplasia, patients who had a total pancreatectomy and those with less than 6 months of follow-up after surgical resection were excluded from the study.
Patients with a primary resection of IPMN-associated invasive carcinoma were excluded from the clinical analysis, as these patients experience distant metastatic recurrence rather than local progression in the remnant pancreas. Therefore, only patients undergoing pancreatic resection for noninvasive IPMN were included.
A positive margin was defined as presence of IPMN, regardless of the grade of dysplasia, at a final resection margin. A positive family history was defined as pancreatic cancer diagnosis in a firstor second-degree relative. 14, 22, 23 Patients with initial noninvasive IPMN were classified into 3 different radiological categories of local progression ( Fig. 1): (1) ''BD progression,'' defined as a radiological finding of a new branch-duct IPMN, a clinically significant increase in size of an existing BD-IPMN, or development of a new solid component within an existing BD-IPMN; (2) ''MD progression,'' defined as a radiological finding of main duct dilation suspicious for IPMN; (3) ''separate solid mass progression,'' defined as the development of a new PDAC in the remnant pancreas or the development of a locally unresectable or metastatic pancreatic cancer confirmed by imaging or biopsy. In the second category, postoperative main duct dilation stable on follow-up imaging in patients who underwent a pancreaticoduodenectomy was not considered progression but likely postoperative stricture of the pancreatic anastomosis. The time to disease progression was calculated from the time of pancreatic resection to diagnosis of progression on follow-up imaging.
Statistical Analyses
Continuous variables are presented as median and interquartile range (IQR) and were compared using a Wilcoxon-Mann-Whitney test. A Chi-squared test or a Fisher exact test was used to compare the categorical variables. Possible risk factors associated with disease progression in the remnant pancreas were evaluated using univariate and multivariate regression models. A backward stepwise elimination method with a threshold of P ¼ 0.20 was performed for the final multivariate model. Kaplan-Meier survival estimates were used to estimate the progression rates in IPMNs with different grades of dysplasia. A P value <0.05 was considered statistically significant. Stata/MP version 12.1 (StataCorp, College Station, TX) was used for statistical analysis.
RESULTS
Pathological Evaluation and Genetic Analyses
Completion Pancreatectomy Following Resection of IPMN
Targeted mutational analysis was performed for the primary IPMN and the progressive lesion of 13 patients who underwent completion pancreatectomy for progression in the remnant pancreas following IPMN resection. The results are summarized in Table 1 and  detailed in Supplementary Table 2 , http://links.lww.com/SLA/B35. The primary neoplasm of these 13 patients included 9 noninvasive IPMNs (3 LGDs and 6 HGDs) and 4 IPMN-associated invasive carcinomas. One of the latter was an IPMN-associated microinvasive cancer (0.4 cm focus of cancer). All resections for IPMN-associated invasive carcinoma were node negative (N0).
Relatedness was determined on the basis of the comparison of the mutations found in the 2 lesions from the same patient. Moreover, in patients who had IPMN at the margin available for DNA extraction, the genetic relationship of both lesions was compared with the lesion at the margin. Invasive and noninvasive components of an IPMN were separately sequenced.
Eight of the 13 patients had margin-negative resections. On the basis of the genetic analysis, the primary and progressive neoplasms were ''likely related'' in only 1 of these 8 patients (case #2), while 5 cases had evidence of independent genetic alterations in the secondary lesion and were classified as ''likely independent.'' The remaining 2 cases were ''indeterminate,'' as they only shared the same KRAS mutation (cases #3 and #5). The single patient with ''likely related'' lesions developed a poorly differentiated PDAC after an initial resection for an IPMN with an associated invasive colloid carcinoma. In this case, the primary and progressive neoplasms shared both KRAS and GNAS mutations, while a TP53 mutation was unique to the primary neoplasm.
Five of the 13 IPMN patients had a positive margin resection. In 2 cases, the 2 neoplasms sequenced were classified as ''likely independent'' (cases #9 and #10) due to the discordant genetic alterations in the 2 tumors. Two cases (cases #12 and #13) were classified as ''likely related,'' based on identical driver gene mutations in the original tumors and subsequent resections. Of note, the ''likely independent'' progressions occurred in patients with LGD at the margin, while there was HGD at the margin in the ''likely related'' progressions. The last case was classified as ''indeterminate'' (case #11) because the primary and the progressive neoplasms shared the same KRAS mutation. Intriguingly, in the ''indeterminate'' (case #11), the subsequent tumor shared the same KRAS mutation with the patient's original invasive IPMN at the resection margin that was different from that seen in the invasive IPMN at the pancreatic head.
IPMNs With Concomitant PDAC
The results of the analysis of 10 patients with IPMN and separate synchronous PDAC are summarized in Table 2 and detailed  in Supplementary Table 3 , http://links.lww.com/SLA/B35. In 3 cases (cases #1, #2, and #4), the IPMN and the concomitant PDAC did not share the same mutations, suggesting that the IPMN and the PDAC were ''likely independent.'' In 2 cases (cases #5 and #7), the PDAC and the IPMN were ''likely related,'' as the two neoplasms shared multiple driver gene mutations. Of interest, both ''likely related'' PDACs had GNAS mutations, which are uncommon in PDACs not associated with IPMN. 19 In 4 cases (cases #3, #6, #8, and #9), results were indeterminate, as the 2 lesions in each case shared a same KRAS mutation. The last case (case #10) had 2 different IPMNs in the head of the pancreas, 1 with LGD and 1 with HGD; the 
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Clinical Validation
Local Progression Following Resection of Noninvasive IPMNs
A total of 260 patients who underwent partial pancreatectomy for a noninvasive IPMN and had more than 6 months of follow-up were identified. Of these, 50 (19%) patients developed disease progression in the remnant pancreas: BD-progression in 32 (64%), MD-progression in 7 (14%), and progression to PDAC in 11 (22%) patients (Table 3) . Of the 11 patients with progression to PDAC, 4 underwent a completion pancreatectomy, while 7 were diagnosed with metastatic or unresectable disease during follow-up and did not undergo an additional pancreatic resection. The median time to disease progression from the original surgical resection was 27 months (IQR 14-53) for patients with BD-progression, 52 months (IQR 38-69) for patients with MD-progression, and 59 months (IQR 32-78) for patients who developed a solid mass in the remnant.
We then evaluated the risk factors associated with development of an IPMN with HGD or an invasive carcinoma (both IPMNassociated invasive carcinoma and conventional PDAC) in the remnant pancreas of patients with surgically resected noninvasive IPMN (Table 4) . By univariate analysis, family history of pancreatic cancer (P ¼ 0.029), HGD in the initially resected IPMN (P ¼ 0.004) (Fig. 2) , and presence of any grade of dysplasia at the pancreatic neck resection margin (P ¼ 0.032) were associated with developing neoplasia in the remnant. On multivariate analysis, only family history [odds ratio (OR) 5.82; 95% confidence interval (95% CI) 1.49-22.78; P ¼ 0.011] and primary resected IPMN with HGD (OR ¼ 9.22; 95% CI ¼ 2.76-20.71; P < 0.001) were confirmed to be independent risk factors.
DISCUSSION
The progression of neoplastic disease within a remnant pancreas following resection of an IPMN is now a well-documented and challenging aspect of the management of IPMN patients. [10] [11] [12] [13] [14] Progression within the remnant pancreas may include the development of a new IPMN, an IPMN-associated cancer, or a conventional PDAC. 14, 15, 24, 25 Our targeted NGS comparing primary resected IPMN and progressive neoplasia in the remnant pancreas of 13 patients permitted us to assess the genetic relationship between the 2 lesions in 10 cases. The metachronous lesions were genetically unrelated in 5 of 8 patients with a negative resection margin and in 2 of 5 patients with a positive margin, while they were genetically related in 1 of 8 negative margin case and 2 of 5 positive margin cases. In both margin-positive cases with genetically unrelated primary/progressive neoplasms, the IPMN at the resection margin harbored LGD and showed genetic discordance with both the primary and the progressive lesions, suggesting that it was an independent multifocal IPMN. On the contrary, in the 2 margin-positive cases with genetically related primary/progressive lesions, the margins harbored HGD. In 1 case, the IPMN at the margin was genetically identical to both the primary and the progressive lesions, suggesting direct extension at the microscopic level. In the remaining 3 cases (2 negative margin and 1 positive margin), the genetic relationship could not be determined.
Among the 10 patients with an IPMN and a separate concomitant PDAC in the same resected specimen, the lesions were genetically independent in 3 cases, while in 2 cases, the IPMN and the PDAC showed the same KRAS and GNAS mutations, suggesting that the 2 lesions were genetically related. In the remaining 5 cases, the genetic relationship could not be determined.
On the basis of these results, we propose that 3 different mechanisms account for the development of neoplastic lesions in the remnant pancreas following resection of IPMN (Fig. 3) . The first mechanism is conceptually the simplest and consists of the transection of the neoplasm at the margin with resulting residual disease. In this mechanism, the primary, secondary, and microscopic margin lesions are all genetically related (Fig. 3A) . The second mechanism consists of intraductal or intraparenchymal metastases. In these cases, no identifiable tumor is present at the margin between the 2 lesions, but the physically separate lesions are genetically related (Fig. 3B) . Finally, the third mechanism is through the independent development of 2 separate ''primary'' lesions. In these cases, the 2 lesions are genetically unrelated (Fig. 3C) .
Other studies have attempted to assess the genetic relatedness of multifocal IPMN, and their results support the mechanisms described above. Tamura et al, 17, 26 based only on KRAS and GNAS mutations, have suggested that multisegmental MD-IPMNs can be 
Seven patients had a resection margin positive for HGD at the final histological examination. In 3 cases, the surgeon decided not to proceed with a completion pancreatectomy based on the patients' advanced age and medical problems, balancing the risk of residual neoplasia with potential disability from brittle diabetes following completion pancreatectomy. In 4 cases, although the definitive margin status on the final pathological report was positive for HGD, the intraoperative margin was called negative, precluding additional resection. clonally related, as described in our proposed second mechanism. However, they did not consider the limit of assessing the genetic relationship when only 1 of the drivers presents the same mutation in both lesions. In addition, previous molecular analyses demonstrated that the majority of multifocal BD-IPMNs are genetically unrelated, 16 as in our proposed third mechanism (Fig. 3) . However, our proposed mechanisms do not represent the only explanation of our data. An alternative explanation for our ''likely independent'' lesions is that the progressive lesion was seeded by subclones of IPMN cells that originated in the primary tumor but were not present in the sample used for genetic analysis. Other studies have already demonstrated polyclonality of IPMN epithelium within the same lesion. 20, 27 Although we identified several neoplasms with multiple different mutations in the same driver gene, in most cases, we observed a predominant mutation in each gene with the highest concentration of mutant reads. This suggests that each neoplasm did have some clonal mutations that would be shared if the primary and progressive neoplasms were related. As such, the possibility of the progressive neoplasm arising from unsampled genetically distinct subclones of the primary tumor is less consistent with our data than the other models proposed.
One proposed explanation for the multifocal nature of IPMN and the related observation of progression in the remnant following resection is that a ''field defect'' exists that predisposes the entire pancreas to the development of neoplasia. 28 In 2 of the 3 mechanisms described above, the primary lesion serves as the source of neoplastic cells and progression is by dissemination of this lesion-either directly or indirectly by ''skipping'' throughout the pancreas. These mechanisms do not require a field defect, as a single neoplasm accounts for the primary and progressive disease. In the third mechanism, 2 independent neoplasms arise in the same pancreas, which could support the proposed ''field defect'' model. However, the absence of shared detectable driver mutations among the lesions suggests that, if an underlying field defect exists, it does not involve the driver genes that we used for genetic analysis.
Some limitations of our cohort for genetic analysis should be noted. First, this cohort is based on progressive pancreatic neoplasms that reached clinical criteria for a completion pancreatectomy, and as such may not be representative of all patients with progressive disease. In addition, the majority of patients with invasive carcinoma after surgery for IPMN were not resected because of an advanced disease stage; therefore, it is possible that lesions included in this study were characterized by a less aggressive biology.
In order to provide information that would be useful in clinical decision-making, we investigated a cohort of 260 patients who underwent surgical resection of noninvasive IPMNs for risk factors associated with development of metachronous disease in the remnant LGD at 1, 5, and 10 years was 0%, 1%, and 6% and increased to 0%, 23%, and 52% for IPMNs harboring HGD.
pancreas. The rate of local progression in our cohort was 19%, which is consistent with our previous studies. 14, 15 We report that a family history of pancreatic cancer is a significant risk factor for the development of any type of progression in the remnant pancreas, and in particular of a high-risk neoplasm (Supplementary Table 4 , http://links.lww.com/SLA/B35). This is consistent with previous data on patients with familial pancreatic cancer, as more precursor lesions are observed in their pancreata than in patients without a family history. [29] [30] [31] These results highlight the likelihood of multifocal neoplasia in patients with a family history of pancreatic cancer. 9, 14, 32, 33 Although our study was underpowered to capture any differences in the strength of this association between first-and second-degree relatives, it does suggest that second-degree relatives also harbor an increased risk of progression. We also observed that HGD in the primary IPMN is an independent risk factor for development of a high-risk neoplasm in the remnant pancreas. Accordingly, several other studies have also suggested the possibility of HGD as risk factor for progression, and others have reported cases of systemic recurrence after resection of IPMN with HGD. 4, 5, 8, 15, 17, 32 Our study has important implications for clinical management, as we demonstrate that an IPMN harboring HGD predicts an overall more aggressive biology, with a relatively high risk (13%) of developing a subsequent HGD or PDAC lesions, particularly when other risk factors such as a positive family history are present. For these high-risk patients, interventions may prevent progression, including both chemoprevention and complete pancreatic resection. In order for either of these approaches to be implemented, further investigation is necessary to understand the risks and benefits, including studies to examine the natural history of a large population of patients with resected HGD and studies to better understand the long-term effects of the apancreatic state.
Our clinical analysis of 260 patients showed the expected higher tendency of noninvasive IPMNs with HGD at the resection margin to develop a high-risk lesion in the remnant pancreas. These results are corroborated by our genetic analysis that confirms that resection margins harboring HGD are a potential source of disease progression in the remnant pancreas. On the basis of these findings, we speculate that while an IPMN with LGD at the resection margin might not necessitate additional resection, achieving a negative margin when HGD is present may be of importance. These data, along with the international consensus guidelines and the European guidelines, suggest that an additional resection is necessary only if HGD is found at the pancreatic margin during surgical resection. [34] [35] [36] In summary, we suggest 3 distinct mechanisms for metachronous pancreatic disease following resection of IPMN: tumor transected at a margin, intraparenchymal spread of neoplastic cells, and independent multifocal lesions. Our results, together with a growing body of literature, highlight the need for careful long-term follow-up of patients after surgical resection of an IPMN. Future efforts should confirm these findings in larger patient cohorts as well as identify additional patient groups at an increased risk for metachronous disease who would benefit from additional interventions. Large multicenter trials and consequent expert meetings are necessary to address the best frequency and modality to follow these patients.
